LUND, Sweden, June 29, 2020 /PRNewswire/ -- Immunovia AB (publ)
("Immunovia") today announced the company will be presenting
at the 52nd EPC-IAP annual meeting on July 2, 2020. This year's event will be
held virtually and will be the place to watch and listen to great
lectures and latest research in Pancreatology. The
registration for this year's event is open and can be made via this
link: https://www.epc2020.eu/
Details on Immunovia's Satellite Symposium:
Date: July 2, 2020
Time: 12.20-12.40 CET
Presentation Title: First-In-Class IMMray™ PanCan-d
Enters Final Clinical Validation Stages for launch Q4 2020 for
Early Detection of Pancreatic Cancer
Presented by: MD Thomas King, Medical Director,
Immunovia. The Q&A session will be hosted by PhD Laura
Chirica, Chief Commercial Officer, Immunovia.
For more information on the program go here:
https://www.epc2020.eu/programme/programme
About EPC
The European Pancreatic Club (EPC) is a non-profit,
international scientific organization dedicated to the study of the
pancreas. EPC was founded in 1965, with the idea to bring together
basic scientists and clinicians in an informal atmosphere to
promote friendship and research communication between them.
Therefore, EPC has provided a platform for pancreatologists for
five decades. EPC has strong connections with various European
National Pancreatic Societies (from 22 countries).
About IAP
The International Association of Pancreatology (IAP) is a unique
international organisation established in 1985. IAP provides a
pivot and glues national and regional societies for the common
cause of promoting Pancreatology throughout the world. It has a
unique model where members of various national societies are
accorded dual membership of IAP and the parent society. At present,
it has >3500 members comprising of basic scientists and clinical
investigators from 32 countries exploring pancreatic biology and
pathophysiology in order to find newer treatment and improve
outcomes for pancreatic disorders.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q4
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
For more information, please contact:
Julie Silber, Director of
Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-to-present-a-satellite-symposium-at-the-european-pancreatic-club--epc----international-ass,c3144563
The following files are available for download:
https://mb.cision.com/Main/13121/3144563/1271583.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/immunovia-to-present-a-satellite-symposium-at-the-european-pancreatic-club-epc---international-association-of-pancreatologys-iap-annual-meeting-july-2-2020-301085097.html
SOURCE Immunovia AB